ALFA Finder
15:58 IST
NSE
Earnings Call
Sai Parenterals Earnings Call: Key Takeaways
Sai Parenterals reports Q4 FY26 consolidated revenue of ₹198cr and EBITDA of ₹29cr, following the Noumed acquisition. Standalone FY26 PAT grew 64% YoY.
Sai Parenterals Ltd
- Share price
- ₹505.95
- Market cap
- ₹2,235 Cr
- Revenue (annual)
- ₹381.0 Cr
- Net profit (annual)
- ₹14.26 Cr
- P/E (TTM)
- 89.7×Sector 43.8×
- Promoter holding
- 51.16%+0.00% QoQ
- FII holding
- 2.85%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Other Announcement 7Earnings Call 6Financial Results 4Results Update 3New Order Win 3Management Change 3Board Meeting Outcome 3Board Meeting Date 3Merger & Restructuring 2Fund Raise 2Annual General Meeting 2Acquisition 2Annual Report 1
Time
41 announcements with these filters
20:13 IST
BSE
Results Update
Sai Parenterals Results Update
Sai Parenterals reported FY26 revenue of ₹380.99 Crore, marking 140.37% growth. Robust performance was driven by CDMO exports and successful integration of its Australian subsidiary.
- Value
- ₹381.0 Cr
17:28 IST
NSE
Fund Raise
Sai Parenterals Fund Raise of ₹285 Cr
Sai Parenterals Limited confirmed zero deviation in utilizing its ₹285 Crore IPO proceeds. The funds were deployed across expansion, R&D, and debt repayment as planned.
- Value
- ₹285.0 Cr
16:33 IST
BSE
Financial Results
Sai Parenterals Q3 FY26 Results: Net Loss of ₹6.7 Cr
Sai Parenterals Ltd reported revenue from operations of ₹96.2 Cr and a net loss of ₹6.7 Cr for Q3 FY26.
- Key figure
- Net loss ₹6.7 Cr
16:31 IST
BSE
Financial Results
Sai Parenterals Financial Results
Sai Parenterals approved audited standalone and consolidated financial results for the year ended March 31, 2026. The board meeting concluded successfully with no other material developments.
15:47 IST
BSE
Board Meeting Date
Sai Parenterals Board Meeting Date
Sai Parenterals scheduled a board meeting for May 23, 2026. Directors will consider financial results for the quarter and year ended March 2026.
13:22 IST
NSE
Fund Raise
Sai Parenterals Fund Raise of ₹285 Cr
Sai Parenterals Limited filed its quarterly Monitoring Agency Report regarding IPO proceeds. The entire ₹285 Crore fresh issue remains unutilized in an escrow bank account.
- Value
- ₹285.0 Cr
17:37 IST
BSE
Other Announcement
Sai Parenterals Other Announcement
Sai Parenterals Ltd has announced a delay in submitting its financial results for the quarter and nine months ended December 31, 2025. The delay is due to the pending audit of its recently acquired Australian subsidiary, Noumed Pharmaceuticals PTY Limited. The company expects to submit the results by May 15, 2026.
14:49 IST
BSE
Board Meeting Outcome
Sai Parenterals Board Meeting Outcome
Sai Parenterals Ltd's board approved an unsecured loan of approximately ₹11.91 Crore (AUD 1.75 million) to its wholly-owned subsidiary, Sai Singapore Pte. Ltd. The funds will be used for downstream investment in Noumed Pharmaceuticals Pty Limited, Australia, which is a step-down subsidiary of the company.
- Value
- ₹11.91 Cr
20:24 IST
BSE
Board Meeting Outcome
Sai Parenterals Board Meeting Outcome
Sai Parenterals Ltd has scheduled a Board Meeting on April 20, 2026, to consider a proposal for investing in or lending to its step-down Australian subsidiary, Noumed Pharmaceuticals Pty Limited. The transaction would be executed through its wholly owned subsidiary Sai Parenterals PTE Limited.
17:09 IST
BSE
Other Announcement
Sai Parenterals Other Announcement
Sai Parenterals Ltd has updated its list of Key Managerial Personnel authorized to determine event materiality and make stock exchange disclosures. The authorized persons include the Managing Director, CFO, and Company Secretary. This is a routine regulatory update under SEBI Listing Regulations.